ESG Report 2025

Global Market In the global market, the Group continued to advance its internationalisation strategy with the core objective of improving global access to medicines and contributing to public health capacity building. We placed particular focus on the healthcare needs of low- and middle- income and developing countries and empowered local healthcare development through diversified initiatives. In its bulk medicine segment, the Group has identified low-income and developing countries as core markets and formulated a clear market expansion plan. Currently, its sales network covers nearly 80 countries and regions, including Europe, India, the Middle East, South America and Southeast Asia, serving over 400 overseas customers, and holds a leading position in the global upstream penicillin antibiotic industry. The Group's intermediate products and bulk medicine have obtained official certifications from multiple countries, including EU CEP, US FDA, and approvals from Germany, India, South Korea, Japan, Brazil, Mexico, etc., reflecting international market recognition of the Group's product quality. In the human-used finished products segment, the Group possesses a wide range of generic drugs including antibiotics, insulin and GLP-1 analogues, with competitive advantages across the industrial chain, brand and quality. During the Year, the Group's finished products business achieved its first overseas revenue, successfully winning a tender from the Brazilian Ministry of Health for human insulin injection, with export volumes setting a record for similar Chinese products. Overseas Business Revenue 4 01. RMB billion Number of Overseas Certifications 66 Number of Overseas Registrations 151 66 Number of Overseas Countries / Regions Covered Nearly 80 Serving Overseas Customers 0 Over 40 Species of Products Exported Overseas During the Year 59 The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report